CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics' stock has been influenced by the FDA approval of exa-cel, which served as a positive catalyst. In October 2025, the stock surged by 7% following updated guidance from a regulatory agency. However, the stock also experienced a decline of approximately 10% in October 2025 after Intellia Therapeutics paused Phase 3 trials. Analyst ratings have varied, with some firms raising price targets and issuing "buy" ratings, while others maintained "equal weight" ratings. Insider trading activity has been noted, with CEO Samarth Kulkarni and General Counsel James R. Kasinger selling shares, while Director Douglas A Treco purchased shares. The company reported a 72.5% year-over-year increase in revenue despite negative margins and a GAAP net loss for the quarter ending June 30, 2025.

Given the nature of CRISPR Therapeutics' products and services, there is no apparent demand seasonality. The need for these medicines is driven by disease prevalence and patient eligibility rather than cyclical or seasonal factors.

CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using its CRISPR/Cas9 gene-editing platform. Its core business revolves around the CRISPR/Cas9 technology, which allows for precise alteration of genomic DNA sequences. Its therapy, exa-cel, has received FDA approval for treating sickle cell disease and beta-thalassemia. The company's pipeline includes therapeutic programs targeting hemoglobinopathies, immuno-oncology, autoimmune diseases, type 1 diabetes, and cardiovascular diseases.

CRISPR Therapeutics AG is headquartered in Zug, Switzerland, and maintains operations in the United States, with offices and R&D facilities in Boston, Massachusetts, and San Francisco, California, and a manufacturing facility in Framingham, Massachusetts. The company also has an office in London, United Kingdom.

CRISPR Therapeutics has maintained a strong brand reputation, marked by recognition for its work in gene editing. In June 2025, the company was named to the TIME 100 Most Influential Companies list. The company has also received other accolades, including the NEVY Award in Patient Impact 2024, SCRIP Award 2024, recognition in TIME Best Inventions 2024, and being named a Fierce50 Honoree in Innovation 2024.

Major institutional owners of CRISPR Therapeutics AG include ARK Investment Management LLC, Capital Research and Management Company, BlackRock, Inc., and UBS Asset Management AG. ARK Investment Management LLC increased its stake in the company during the second quarter of 2025. Among individual owners, CEO Samarth Kulkarni and General Counsel James R. Kasinger have engaged in selling shares, while Director Douglas A Treco has made share purchases.